Browsing Tag
Immunotherapy
45 posts
Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma?
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
What the LEGION-100 trial could mean for the future of combination immunotherapy strategies
Can the LEGION-100 trial redefine immunotherapy strategies? Explore what Syncromune Inc.’s approach means for oncology and future cancer treatments.
How tetrahedral antibody design may improve efficacy and safety in immune-mediated diseases
Biomolecular Holdings LLC patents tetrahedral antibodies. Discover how this design could reshape efficacy and safety in immune-mediated diseases.
How next-generation masking strategies could reshape PSMA-directed T cell engager development
How Janux Therapeutics is advancing masked T cell engagers with JANX014. Find out what this means for prostate cancer treatment and immunotherapy.
Bristol Myers Squibb (NYSE: BMY) expands Opdivo into frontline Hodgkin lymphoma, strengthening immuno-oncology leadership
Bristol Myers Squibb expands Opdivo in Hodgkin lymphoma. Discover how this reshapes treatment strategy, competition, and long-term oncology trends.
What AACR 2026 could reveal about Immunocore Holdings plc’s long-term immunotherapy durability (NASDAQ: IMCR)
Can Immunocore’s five-year KIMMTRAK data reshape oncology expectations? Discover the strategic, clinical, and investor implications now.
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?
Could subcutaneous PD-1 therapy reshape cancer treatment in China? Explore Junshi Biosciences’ toripalimab filing and its impact on oncology logistics.
Is pelareorep gaining traction? Oncolytics Biotech’s updated GOBLET data draws investor focus to third-line anal cancer
Find out why Oncolytics Biotech’s updated GOBLET cohort 4 data is drawing investor attention to pelareorep’s role in third-line anal cancer.
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care.